Alterity Therapeutics (ATHE) Cash & Equivalents (2015 - 2025)

Alterity Therapeutics has reported Cash & Equivalents for 11 years, with the latest figure at $32.3 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 988.88% year-over-year to $32.3 million; the trailing twelve-month figure through Dec 2025 stood at $32.3 million (up 988.88% YoY), and the FY2025 full-year result was $21.2 million, up 154.95% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $32.3 million, up from $21.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $32.3 million in Q4 2025, with the low at $126388.8 in Q2 2024.
• Average Cash & Equivalents over 5 years is $15.5 million, with a median of $18.9 million recorded in 2025.
• Year-over-year, Cash & Equivalents plunged 99.37% in 2023 and jumped 16702.03% in 2025.
• Tracing ATHE's Cash & Equivalents over 5 years: stood at $27.0 million in 2021, then plunged by 38.24% to $16.6 million in 2022, then sank by 51.82% to $8.0 million in 2023, then plunged by 63.01% to $3.0 million in 2024, then surged by 988.88% to $32.3 million in 2025.
• The last three Cash & Equivalents figures came in at $32.3 million (Q4 2025), $21.2 million (Q2 2025), and $3.0 million (Q4 2024), per Business Quant data.

Peer Comparison